Results 101 to 110 of about 6,619 (182)

Tolvaptan-Loaded Tomato-Derived Nanovesicles: Characterization and Evaluation of Cytotoxicity, Wound Healing Potential and the Effects on Cyst Formation in Renal Cell Lines [PDF]

open access: yes
Purpose: Plant-derived nanovesicles (PDNVs) are promising candidates for next-generation drug delivery system due to their scalability, low cytotoxicity and immunogenicity, and efficient cellular uptake.
Mammadova, Ramila   +17 more
core   +1 more source

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis

open access: yesFrontiers in Pharmacology
Background: Tolvaptan, a selective vasopressin V2-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15 ...
Hongzhong Liu   +10 more
doaj   +1 more source

Nanoplasmonic sensing as a rapid and sensitive methodology to investigate tolvaptan loaded plant-derived nanovesicles and liposomes [PDF]

open access: yes
Plant-derived nanovesicles (PDNVs) are potential next generation carriers for drug delivery. However, the systemic incorporation of drugs into PDNVs and their quality control still needs extensive research. Previous works showed that Solanum lycopersicum
Mammadova, Ramila   +7 more
core   +1 more source

Effects of tolvaptan on brain water content (BWC), plasma and urine sodium and osmolality.

open access: yes, 2015
(A) Tolvaptan treatment did not change BWC in mice. (B) Tolvaptan treatment causes aquaresis in mice as seen by increases in plasma sodium and decreases in urine sodium concentrations.
Susan M. Jones (314065)   +4 more
core   +1 more source

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

open access: yesKidney International Reports
Introduction: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment.
F.J. Roca Oporto   +4 more
doaj   +1 more source

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials

open access: yesCancer Medicine, 2017
Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer‐related hyponatremia is the syndrome of inappropriate antidiuretic hormone (SIADH).
Richard J. Gralla   +6 more
doaj   +1 more source

Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus

open access: yesLife
Antidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but ...
Sua Kim, Chor Ho Jo, Gheun-Ho Kim
doaj   +1 more source

The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review

open access: yesStudia Medyczne
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature.
Anna Gruszczyńska   +4 more
doaj   +1 more source

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes

open access: yes, 2020
Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Lu
core  

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan

open access: yes
Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2.
Onishi, Hideki   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy